News from synthetic biologics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

May 19, 2015, 09:30 ET
Synthetic Biologics, Inc. Logo. (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics' SYN-004 Microbiome-Protecting Preclinical Data Highlighted in Late-Breaking Poster at Digestive Disease Week® 2015

Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting...

May 18, 2015, 11:17 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics' Novel SYN-010 Preclinical Data Featured in Digestive Disease Week® Poster

Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting...

May 11, 2015, 16:01 ET
Synthetic Biologics, Inc. Logo

Synthetic Biologics Reports First Quarter 2015 Financial Results and Operational Highlights

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome...

May 07, 2015, 06:56 ET
Synthetic Biologics, Inc. Logo.

Maureen Early Named Vice President, Commercial of Synthetic Biologics

Synthetic Biologics, Inc. (NYSE MKT: SYN), a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while...

May 04, 2015, 06:57 ET
Synthetic Biologics, Inc. Logo

Steven Shallcross Named Chief Financial Officer of Synthetic Biologics

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapeutics focused on protecting the microbiome, as well as...

Apr 30, 2015, 06:57 ET
Synthetic Biologics, Inc. Logo

Synthetic Biologics to Host First Quarter 2015 Investor Conference Call

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Apr 27, 2015, 06:56 ET
Synthetic Biologics, Inc. Logo.

Posters at ECCMID 2015 Highlight Preclinical Data from Synthetic Biologics' Novel SYN-005 Monoclonal Antibody Combination for the Treatment and Prophylaxis of Whooping Cough (Pertussis)

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a...

Apr 01, 2015, 06:56 ET
Synthetic Biologics, Inc. Logo

Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015

Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Mar 30, 2015, 06:57 ET
Synthetic Biologics, Inc. Logo

Synthetic Biologics Initiates Phase 2a Clinical Trial of SYN-004 to Protect the Microbiome and Prevent C. difficile

Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Mar 19, 2015, 06:57 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics Announces Positive Pharmacokinetics Data from Phase 1a and 1b Trials of SYN-004 to Protect the Microbiome and Prevent C. difficile Infection

Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Mar 16, 2015, 06:56 ET
Synthetic Biologics, Inc. Logo

Synthetic Biologics Reports Year End 2014 Financial Results and Operational Highlights

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Mar 11, 2015, 06:56 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics' SYN-004 Data for Protection of Microbiome Selected for Late-Breaking Poster Presentation at Digestive Disease Week® 2015

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Mar 09, 2015, 06:57 ET
Synthetic Biologics, Inc. Logo

Synthetic Biologics to Report Year End 2014 Financial Results

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Mar 03, 2015, 06:57 ET
MM19465LOGO

Synthetic Biologics to Present at the 27th Annual ROTH Conference

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Mar 02, 2015, 06:57 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics Announces Two Poster Presentations of Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at ECCMID 2015

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Feb 17, 2015, 06:56 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics Announces Poster Presentation of C-IBS Candidate Therapy Data at Digestive Disease Week® 2015

Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Feb 10, 2015, 06:56 ET
Synthetic Biologics, Inc. Logo

Synthetic Biologics Announces Positive Topline Results from Phase 1b Trial of SYN-004 to Protect the Microbiome and Prevent C. difficile Infection

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Feb 03, 2015, 06:56 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics to Present at the 2015 BIO CEO & Investor Conference

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Jan 07, 2015, 06:58 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics to Present at the Biotech Showcase™ 2015 Conference

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Dec 30, 2014, 07:58 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics Announces First Patient Dosed in Phase 1b Clinical Trial of SYN-004 for the Prevention of C. difficile Infection

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...